Structure (69d6387b 794f 415d 8013 23cca0a6984f 01)
Duloxetine Capsule, Delayed Release
Product Images NDC 68788-8608
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-8608). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 02)
This text presents data on the proportion of patients experiencing relapse over time on placebo versus duloxetine treatment. The graph shows the time from randomization to relapse in days using the Kaplan-Meier estimator method. The data can be analyzed to evaluate the effectiveness of duloxetine in preventing relapse in comparison to a placebo.*
Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 03)
The data provided shows the proportion of patients experiencing a relapse over a certain period, based on the treatment received (Placebo or Duloxetine) and the time from randomization to relapse in days. The information is analyzed using the Kaplan-Meier estimator method, enabling a survival analysis to evaluate the effectiveness of the treatments in preventing relapses.*
Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 04)
Percentage of Patients Improved in a clinical trial comparing different doses of Duloxetine (60 mg and 20 mg) and Placebo in the treatment of pain. The data shows the percentage of improvement in pain from baseline for each treatment group.*
Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 05)
Fig 5 (69d6387b 794f 415d 8013 23cca0a6984f 06)
Percentage of Patients Improved in pain levels when treated with Duloxetine 60 mg, either twice daily or once daily, compared to Placebo. The percentage of improvement is displayed in the form of a table, showing the range from 0 to 100 percent.*
Fig 6 (69d6387b 794f 415d 8013 23cca0a6984f 07)
This text provides data on the percentage of patients improved with different dosages of Duloxetine and a placebo. It includes information on the percentage of pain improvement from baseline.*
Fig 7 (69d6387b 794f 415d 8013 23cca0a6984f 08)
This is a chart showing the percentage of pediatric patients aged 13 to 17 years old with Juvenile Fibromyalgia Syndrome achieving various levels of pain relief at week 12 in Study FM-4. The chart compares patients taking Duloxetine 60mg once daily vs. a Placebo. The pain relief is measured using the Brief Pain Inventory - Modified short Form: Adolescent Version Average Pain Score. Duloxetine-treated patients started with 30 mg once daily for 1 week and then titrated to 60 mg once daily for 12 weeks.*
Figure 8 (69d6387b 794f 415d 8013 23cca0a6984f 09)
Percentage of Patients Improved is shown in the chart for Placebo and Duloxetine 60/120 mg once daily. The chart represents Percent Improvement in Pain from Baseline (BOCF).*
Figure 9 (69d6387b 794f 415d 8013 23cca0a6984f 10)
This text shows the percentage of patients improved with Duloxetine 60 mg compared to a placebo. It indicates a 100% improvement with Duloxetine. The chart also displays the percent improvement in pain from baseline using the last observation carried forward (BOCF) method.*
Figure 10 (69d6387b 794f 415d 8013 23cca0a6984f 11)
Percentage of Patients Improved: 100% with placebo and duloxetine 60/120 mg once daily. The graph shows the percent improvement in pain from the baseline.*
Duloxetine Delayed-release Cap Usp 30mg (69d6387b 794f 415d 8013 23cca0a6984f 13)
This is a description for Duloxetine Delayed-Release Capsules USP 30mg, a generic version of Cymbalta. Each capsule contains 33.7mg of Duloxetine Hydrochloride equivalent to 30mg. It is manufactured by Lupin Limited. The warning advises storing at 25°C with excursions permitted to 15°-30°C. The capsules are blue and white with the imprint "LU Q02." The package includes information on lot number, batch number, expiration date, and instructions in Spanish. The drug is intended for the patient it was prescribed, and it is essential to keep it out of children's reach.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
